Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 8/20 | 0.61 |
| ▸ | GUCY1B1 | Q02153 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.41 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041587 | 0.94 | GUCY1A1 (0.54) | GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1 | |
| SCHEMBL1781591 | 0.93 | GUCY1A1 (0.62) | GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1 | |
| SCHEMBL1781125 | 0.92 | GUCY1A1 (0.61) | GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1 | |
| SCHEMBL1782030 | 0.92 | GUCY1A1 (0.61) | GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1 | |
| SCHEMBL3039197 | 0.91 | GUCY1A1 (0.56) | GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1 | |
| SCHEMBL8027819 | 0.91 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1 | |
| SCHEMBL1780667 | 0.91 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1 | |
| SCHEMBL1783939 | 0.90 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1 | |
| SCHEMBL3997165 | 0.90 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1 | |
| SCHEMBL3997091 | 0.89 | GUCY1A1 (0.60) | GUCY1A1GUCY1B1KDM4EHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | GUCY1A1 3/4885GUCY1B1 1/4885KDM4E 1970/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | GUCY1A1 3/4885GUCY1B1 1/4885KDM4E 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.